Tazeen Ahmad

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company's preliminary figures.  The earnings preview triggered a brief run in the stock this week — one bulls...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S. The deal secures Sarepta a $1.15 billion upfront payment — $750 million in cash and $400 million in an...

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 million equity raise earlier this week. While further financing may be needed to make the company launch ready, the recent equity raise has provided “some cushion,” according to Bank of America. The Analyst BofA’s...

Sarepta Therapeutics Inc (NASDAQ: SRPT)'s new drug application for its second Duchenne muscular dystrophy drug received a a complete response letter from the FDA on Monday.  The Analysts Nomura Instinet analyst Christopher Marai maintained a Buy rating on Sarepta with a $230 price...

Positive top-line results from a competitor’s prostate cancer drug trial led Bank of America to downgrade Clovis Oncology Inc (NASDAQ: CLVS). The Analyst Bank of America's Tazeen Ahmad downgraded Clovis Oncology from Buy to Neutral while lowering the price target from $13 to $7. The...

Prevail Therapeutics Inc (NASDAQ: PRVL) shares traded higher on Monday after a pair of Wall Street analyst initiated bullish coverage of the stock. The Analyst Bank of America analyst Tazeen Ahmad initiated coverage of Prevail with a Buy rating and $15 price target. The Thesis Ahmad said Prevail...

DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) shares were losing more than half of their value in Thursday trading following an update on the company's lead pipeline candidate. What Happened DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application,...

Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. The Analyst Analysts Tazeen Ahmad maintained a Buy on GW Pharma with a $190 price...

Zogenix, Inc. (NASDAQ: ZGNX)'s lead asset ZX008 presents a multibillion-dollar opportunity, according to Bank of America Merrill Lynch. The Analyst Analyst Tazeen Ahmad initiated coverage of Zogenix with a Buy rating and $63 price target, suggesting 29-percent upside. The Thesis BofA's...

Myokardia Inc (NASDAQ: MYOK) stock is up 290 percent year-over-year, but upcoming stimulants could drive additional outperformance, according to Bank of America Merrill Lynch.  The Analyst BofA's Tazeen Ahmad initiated coverage of Myokardia with a Buy rating and $71 price target...

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) shares have been sensitive to recent news around Gocovri, the firm’s leading pipeline candidate. The drug is a proven gateway to the stock and lured an industry analyst in Tuesday. The Rating Bank of America Merrill Lynch analyst Tazeen Ahmad...

Clinical-stage biopharma resTORbio, Inc. (NASDAQ: TORC) went public Jan. 26, offering 5.67 million shares at $15 each.  The Analyst Bank of America Merrill Lynch analyst Tazeen Ahmad initiated coverage of Restorbio shares with a Buy rating and $23 price target. The Thesis...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported its Q3 2016 results, with earnings below expectations, driven by higher than anticipated opex. Tazeen Ahmad of Bank of America upgraded the rating on the company from Neutral to Buy, while lowering the price target from $39 to $35. The...

Shares of Theravance Inc (NASDAQ: THRX) fell more than 12 percent Wednesday morning after the company's commercial partner, GlaxoSmithKline plc (ADR) (NYSE: GSK), disclosed topline results from SUMMIT. Theravance's trial attempted to prove survival benefits for Breo in COPD patients and failed to...